Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. - Leleu X; Hulin C; Lambert J; Bobin A; Perrot A; Karlin L; Roussel M; Montes L; Cherel B; Chalopin T; Slama B; Chretien ML; et al. (Nature medicine, 2024)